Data provided by the Entrepreneurial Group of the Biotechnological and Pharmaceutical Industries of Cuba (BioCubafarma) show that as part of phase III of clinical trials on Soberana 02, which started on March 8, 35,153 of 44,010 subjects have been vaccinated so far in eight municipalities in Havana.
Soberana 02, which was developed by the Finlay Vaccines Institute (IFV), is also being used in an intervention study that involves 150,000 subjects from high-risk sectors of the population, including 74,665 health workers and from the scientific complex, 47,266 of whom have already received the first injectable dose of the vaccine.
On the other hand, Abdala, created by the Genetic Engineering and Biotechnology Center (CIGB), has been administered to 19,524 of 48,000 volunteers as part of its phase III of clinical trials in the eastern provinces of Santiago de Cuba, Granma and Guantanamo.
Abdala is also being used in an intervention study against Covid-19 that involves 124,000 volunteers from the health sector and the biopharmaceutical industry in eight regions of Havana.
Cuban scientists have developed three other vaccine candidates against the SARS-CoV-2 coronavirus that causes Covid-19: Soberana 01 and Soberana Plus (also by the IFV), and Mambisa, which is administered nasally and was also created by the CIBG.
jg/mgt/rbp
